Preferred Label : mogamulizumab;

MeSH note : a defucosylated humanized anti-CCR4 antibody under phase I clinical trials (2010);

CISMeF synonym : AMG 761; KW 0761;

MeSH hyponym : AMG761; AMG-761; KW0761; KW-0761; KM-8761;

Is substance : O;

UNII : YI437801BE;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.cadth.ca/fr/mogamulizumab
2022
false
false
false
Canada
French
canada
drug evaluation
mogamulizumab
adult
mycosis fungoides
sezary syndrome
Recurrent Sezary Syndrome
Refractory Sezary Syndrome
antineoplastic agents
mogamulizumab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
mogamulizumab
mogamulizumab
mogamulizumab
antineoplastic agents
antineoplastic agents
orphan drug production
mycosis fungoides
sezary syndrome
infusions, intravenous
continuity of patient care
receptors, ccr4
product surveillance, postmarketing
adult
aged
pregnancy
breast feeding
drug evaluation, preclinical
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3083094/fr/poteligeo
2019
false
false
false
France
treatment outcome
mogamulizumab
mogamulizumab
mogamulizumab
infusions, intravenous
antineoplastic agents
antineoplastic agents
adult
mycosis fungoides
sezary syndrome
Progression-Free Survival
orphan drug production
evaluation of the transparency committee
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.